Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $130.8 million.

  • Summit Therapeutics' Share-based Compensation rose 57503.48% to $130.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $631.7 million, marking a year-over-year increase of 119652.91%. This contributed to the annual value of $51.0 million for FY2024, which is 26136.23% up from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Share-based Compensation is $130.8 million, which was up 57503.48% from $478.8 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Share-based Compensation high stood at $478.8 million for Q2 2025, and its period low was $705000.0 during Q3 2023.
  • Its 5-year average for Share-based Compensation is $37.4 million, with a median of $4.0 million in 2022.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 7480.34% in 2023, then soared by 421803.75% in 2025.
  • Summit Therapeutics' Share-based Compensation (Quarter) stood at $5.6 million in 2021, then crashed by 52.7% to $2.7 million in 2022, then skyrocketed by 229.31% to $8.8 million in 2023, then rose by 25.84% to $11.0 million in 2024, then skyrocketed by 1087.12% to $130.8 million in 2025.
  • Its Share-based Compensation was $130.8 million in Q3 2025, compared to $478.8 million in Q2 2025 and $11.1 million in Q1 2025.